A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis
نویسندگان
چکیده
منابع مشابه
PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
Methods 112 children with active, persistent sJIA were randomised 2:1 to receive TCZ by body weight (12 mg/kg <30kg or 8 mg/kg ≥30kg) or placebo IV every 2 weeks for 12 weeks and continued in an ongoing, TCZ open-label extension. [1]. Worst common toxicity criteria (CTC) neutropenia grade (grade 1, ≥1.5 and <2.0 × 10/L; grade 2, ≥1.0 and <1.5 × 10/L; grade 3, ≥0.5 and <1.0 × 10/L; grade 4, <0.5...
متن کاملR202Q Mutation of Mediterranean Fever Gene in Iranian patients with Systemic-onset Juvenile Idiopathic Arthritis
Background: Systemic-onset Juvenile Idiopathic Arthritis (SoJIA) is an autoinflammatory disease with complex genetic trait starts in children less than 16 years of age with fever and cutaneous rash. Despite, the main genetic factors that may play a role in SoJIA have not yet been identified. High level of interleukin-1beta in the blood of SoJIA patients has been reported. The production and sec...
متن کاملMacrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
Introduction Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Changes in therapies, including biologics, have been associated with the onset of MAS. Interleukin-6 (IL-6) plays a major pathogenic role in sJIA; data in animals suggest that high IL-6 levels contribute to the triggering of MAS [1]. Treatment with the ...
متن کاملTocilizumab in the treatment of systemic juvenile idiopathic arthritis
Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threa...
متن کاملSafety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
Results A total of 39 patients (21 boys and 18 girls) were included in this Median age was 7,5 years (range; 3 to 15 years) and median disease duration was 4,2 years (range; 0.5 to 8,3 years). A total of 16 of the 39 patients (25%) entered 52 weeks of continuous tocilizumab treatment. The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infection and g...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis & Rheumatology
سال: 2014
ISSN: 2326-5191
DOI: 10.1002/art.38430